Literature DB >> 10490519

The evolution of liver disease in cystic fibrosis.

S C Ling1, J D Wilkinson, A S Hollman, J McColl, T J Evans, J Y Paton.   

Abstract

OBJECTIVES: To describe prospectively the evolution of liver abnormalities in cystic fibrosis (CF), and to assess their impact on nutritional status. STUDY
DESIGN: 124 children (61 boys) with CF (median age, 5.4 years; range, 0.1-13.9) were followed longitudinally for a median of four years. Annual clinical examination, biochemistry, and ultrasound assessment were performed. Chrispin-Norman score, anthropometry, and bacterial colonisation of airway secretions were measured at each assessment.
RESULTS: At initial assessment, 45% of the patients had no liver abnormalities, 42% had biochemical abnormality, 35% ultrasound abnormality, and 6% had clinical abnormality of the liver. In this cross sectional analysis, abnormal biochemistry was present in 40% of children with ultrasound or clinical abnormalities, but when longitudinal follow up data were analysed, abnormal biochemistry preceded or coincided with abnormal ultrasound or clinical hepatosplenomegaly in three quarters of 53 children developing new abnormalities. Eighty four of 124 children (68%) showed ultrasound or clinical evidence of liver abnormality at some point during the four years of follow up. No association was found between liver disease and nutritional status.
CONCLUSIONS: Hepatic abnormality was common in this group of children with CF, was often predicted by intermittent biochemical abnormalities, and was not associated with deterioration in nutritional status.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10490519      PMCID: PMC1718033          DOI: 10.1136/adc.81.2.129

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  18 in total

Review 1.  Liver disease in cystic fibrosis.

Authors:  M S Tanner; C J Taylor
Journal:  Arch Dis Child       Date:  1995-04       Impact factor: 3.791

2.  Can the histologic changes of cystic fibrosis-associated hepatobiliary disease be predicted by clinical criteria?

Authors:  C J Potter; M Fishbein; S Hammond; K McCoy; S Qualman
Journal:  J Pediatr Gastroenterol Nutr       Date:  1997-07       Impact factor: 2.839

Review 3.  Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group.

Authors:  R J Sokol; P R Durie
Journal:  J Pediatr Gastroenterol Nutr       Date:  1999       Impact factor: 2.839

4.  Ultrasonography in the diagnosis of portal hypertension: diminished response of portal vessels to respiration.

Authors:  L Bolondi; L Gandolfi; V Arienti; G C Caletti; E Corcioni; G Gasbarrini; G Labò
Journal:  Radiology       Date:  1982-01       Impact factor: 11.105

5.  Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.

Authors:  C Colombo; P M Battezzati; M Podda; N Bettinardi; A Giunta
Journal:  Hepatology       Date:  1996-06       Impact factor: 17.425

6.  Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells.

Authors:  J A Cohn; T V Strong; M R Picciotto; A C Nairn; F S Collins; J G Fitz
Journal:  Gastroenterology       Date:  1993-12       Impact factor: 22.682

7.  Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London.

Authors:  I T Gilmore; A Burroughs; I M Murray-Lyon; R Williams; D Jenkins; A Hopkins
Journal:  Gut       Date:  1995-03       Impact factor: 23.059

8.  Liver cirrhosis in cystic fibrosis--therapeutic implications and long term follow up.

Authors:  J Feigelson; C Anagnostopoulos; M Poquet; Y Pecau; A Munck; J Navarro
Journal:  Arch Dis Child       Date:  1993-05       Impact factor: 3.791

9.  Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: a randomized, placebo-controlled, crossover trial.

Authors:  M Merli; S Bertasi; R Servi; S Diamanti; F Martino; A De Santis; F Goffredo; S Quattrucci; M Antonelli; M Angelico
Journal:  J Pediatr Gastroenterol Nutr       Date:  1994-08       Impact factor: 2.839

10.  An ultrasound scoring system for the diagnosis of liver disease in cystic fibrosis.

Authors:  S G Williams; J E Evanson; N Barrett; M E Hodson; J E Boultbee; D Westaby
Journal:  J Hepatol       Date:  1995-05       Impact factor: 25.083

View more
  8 in total

Review 1.  The role of abdominal ultrasound in the diagnosis, staging and management of cystic fibrosis liver disease.

Authors:  Louise Stewart
Journal:  J R Soc Med       Date:  2005       Impact factor: 5.344

2.  Paediatric cholestatic liver disease: Diagnosis, assessment of disease progression and mechanisms of fibrogenesis.

Authors:  Tamara N Pereira; Meagan J Walsh; Peter J Lewindon; Grant A Ramm
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

Review 3.  The gallbladder and biliary tract in cystic fibrosis.

Authors:  Michael P Curry; John E Hegarty
Journal:  Curr Gastroenterol Rep       Date:  2005-05

4.  Liver involvement in cystic fibrosis.

Authors:  Catherine Brigman; Andrew Feranchak
Journal:  Curr Treat Options Gastroenterol       Date:  2006

5.  Transient elastography in patients with cystic fibrosis.

Authors:  Renaud Menten; Anissa Leonard; Philippe Clapuyt; Pierre Vincke; Alexandra-Cristina Nicolae; Patrick Lebecque
Journal:  Pediatr Radiol       Date:  2010-02-05

6.  Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis.

Authors:  Jaclyn R Stonebraker; Chee Y Ooi; Rhonda G Pace; Harriet Corvol; Michael R Knowles; Peter R Durie; Simon C Ling
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-05       Impact factor: 11.382

Review 7.  Intestinal obstruction syndromes in cystic fibrosis: meconium ileus, distal intestinal obstruction syndrome, and constipation.

Authors:  Hubert P J van der Doef; Freddy T M Kokke; Cornelis K van der Ent; Roderick H J Houwen
Journal:  Curr Gastroenterol Rep       Date:  2011-06

8.  The emerging burden of liver disease in cystic fibrosis patients: A UK nationwide study.

Authors:  M B Toledano; S K Mukherjee; J Howell; D Westaby; S A Khan; D Bilton; N J Simmonds
Journal:  PLoS One       Date:  2019-04-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.